Molde

Amyotrophic lateral sclerosis ALS is a severe and fast-progressing nervous system disease with a typical survival time of about 2.5 years after diagnosis. Currently, Riluzole is the only treatment available, and the care for advanced ALS is very costly. Research suggests that increasing access to Nicotinamide Adenine Dinucleotide NAD and activating enzymes called sirtuins might slow disease progression. Nicotinamide riboside NR increases NAD, and Pterostilbene stimulates sirtuins. The study aims to evaluate whether a combination of NR and Pterostilbene can slow neurodegeneration, delay disease progression, improve survival, and enhance quality of life in ALS patients. This extension study follows patients who completed the initial NO-ALS trial, where all participants receive the combination supplement EH301 Nicotinamide Riboside and Pterostilbene. It is an open-label study offering compassionate use and monitoring adverse events. The study will assess if this combination can reduce motor symptom progression, preserve lung function, and increase survival over a one-year follow-up. Participants who completed the original NO-ALS trial will be followed for one year with regular assessments. Researchers will monitor adverse events throughout this period and measure disease progression using the ALS Functional Rating Scale Revised and changes in vital lung capacity. The study aims to provide long-term safety and efficacy data while allowing continued access to the supplement. Total participation duration is one year from enrollment in the extension study.

Researchers are evaluating whether D-serine, a co-agonist of the N-methyl-D-aspartate receptor NMDAR, can improve symptoms and slow progression in Parkinsons disease PD. This randomized, double-blind, placebo-controlled trial involves 100 participants diagnosed with PD within the past 5 years. The study aims to measure changes in clinical severity using the Movement Disorder Society Unified Parkinsons Disease Rating Scale MDS-UPDRS, along with dopaminergic brain activity and cognitive function. Participants will be randomly assigned to two groups that receive both D-serine and placebo during different study periods over 58 weeks. D-serine dosing starts with 2 capsules of 500 mg twice daily in the first week and increases to 4 capsules twice daily thereafter, while placebo capsules are given similarly. After the intervention phase, a 12-week washout period will follow where the study drug is stopped, with a final visit 12 weeks after discontinuation. During the study, participants will undergo clinical evaluations including rating scales and questionnaires, cognitive testing, blood sampling, and dopamine transporter imaging via SPECT scans. Researchers will closely monitor motor and non-motor symptoms, brain dopamine function, and cognitive changes. The trial includes a screening and treatment optimization phase before randomization to ensure stable Parkinsons treatment. This study may provide important insights into D-serines potential effects on Parkinsons disease progression.

Researchers are investigating whether a treatment program using an adapted version of Dialectical Behavior Therapy DBT is feasible, accepted, and useful for adults with autism who have difficulties in emotion regulation. Autism Spectrum Disorder ASD is a lifelong condition with challenges in social interaction, communication, and repetitive behaviors, often accompanied by co-occurring mental health issues. This project aims to improve emotion regulation, relationships, and crisis management to enhance personal goals, reduce suffering, and improve quality of life for autistic adults. The study involves a DBT skills training program tailored to autistic adults, incorporating autism-specific adjustments like simplified skills, more visuals, hands-on training, and sensory accommodations. The intervention includes 2-3 initial sessions focused on treatment orientation, followed by 28 weekly two-hour group skills training sessions led by two therapists, a mid-treatment evaluation session, and a final summary session. Groups consist of approximately 4-6 participants. The intervention period is from August 2025 to February 2027. Participants will be assessed before and after the treatment using scales measuring difficulties in emotion regulation, treatment participation, coping strategies, diary cards, and qualitative interviews. Researchers will track dropout rates, session attendance, homework completion, and participants experiences. The study seeks to provide feasibility and acceptability data for this treatment approach in a naturalistic outpatient psychiatric setting, with a total treatment duration of 28 weeks.

Researchers are investigating whether using custom felt relief can reduce the treatment time for diabetic foot ulcers compared to the standard relief method. The study is conducted by the Surgical Outpatient Clinic at Molde Hospital, which has provided specialized care for diabetic foot ulcers since 2015. The purpose is to optimize current treatment by testing if personalized felt relief shortens the healing process for patients with neuropathic wounds under the foot. The study compares two treatment approaches. One group receives custom felt relief, where felt material is adjusted weekly by cutting it in different ways and layers to fit the wound. The other group receives the standard relief treatment, which involves placing felt shaped like a letter U around the wound once every week. Participants are randomly assigned to one of these two groups and monitored throughout the study. Participants will be involved in weekly treatments where the felt is applied and adjusted as needed. Researchers will measure how long it takes for the wounds to heal, specifically tracking wound healing time between 2 to 8 weeks. The study includes assessments of wound condition and patient progress during this period. The total participation duration depends on the individual healing times, with safety and treatment effectiveness monitored by the clinical team throughout.

This research aims to explore the genetic causes related to the development of Amyotrophic Lateral Sclerosis ALS in Norway. The study focuses on individuals diagnosed with probable or definite ALS according to the El-Escorial criteria. Understanding genetic factors may help in better characterizing the disease and its risk factors over time. Participants diagnosed with ALS will be followed through the Norwegian health-care system. After giving informed consent, they will complete a brief questionnaire about their family history and provide a blood sample. These samples, along with clinical information and consent forms, are sent to the Department of Medical Genetics at Telemark Hospital Trust for ongoing genetic analysis throughout the recruitment period. Participants may choose to receive their genetic results as part of a diagnostic process. During the study, participants will be involved in providing blood samples and completing questionnaires. Researchers will analyze genetic data to identify gene frequency, new ALS genes, and genetic risk factors between 2020 and 2030. The study involves observation only, with no additional treatments. Participation includes genetic testing and data collection to better understand ALS genetics, with the study continuing until 2035.

Researchers are evaluating the effects of personalized exercise treatment on dynamic balance and physical function compared to regular follow-up care in adults with rare neuromuscular disorders, specifically Charcot-Marie-Tooth CMT, Facioscapulohumeral Muscular Dystrophy FSHD, and Myotonic Dystrophy Type 1 DM1. The study aims to see if the exercise intervention group experiences greater improvements in dynamic balance and long-term benefits compared to the control group receiving usual care. Participants in the experimental group will undergo a four-month exercise program that starts with a 12-day personalized exercise regimen at a rehabilitation center, followed by a three-month digital intervention, and then a second 12-day personalized exercise program at the rehabilitation center. The control group will continue with their usual care, which includes hospital and community health system appointments as recommended individually. During the study, participants will be assessed at baseline, 4 months, 10 months, and 16 months for dynamic balance using the Mini-Balance Evaluation Systems Test Mini-BESTest and other measures such as fatigue severity, strength and function, metabolomics, body composition via Dual Energy X-ray Absorptiometry, neuromuscular ultrasound, physical activity, motor unit number estimation, and health-related quality of life questionnaires. The study involves 120 individuals and includes long-term follow-up for the intervention group to monitor sustained effects.

Knee osteoarthritis is a common condition often treated first with non-surgical methods such as exercise. Despite advances in surgery, about 20% of patients who undergo total knee replacement remain dissatisfied with their results. This trial aims to see if doing strength training before surgery can improve leg strength and reduce dissatisfaction after the operation. Participants will be randomly assigned to one of two groups one group will do maximal leg press strength training three times a week at about 85% of their maximum effort for eight weeks before surgery, and the other will receive usual care without the added training. This setup allows researchers to compare the effects of pre-surgery strength training against standard treatment. Throughout the study, leg strength will be measured at multiple points including before surgery, one week before surgery, three weeks after surgery, and up to 12 months post-surgery. The study will also assess patient satisfaction after surgery, along with voluntary muscle activation, knee function, walking speed, chair rising ability, and balance. These evaluations will help determine if pre-surgery training improves recovery and satisfaction over time.

Researchers are conducting an observational study to understand how new immunotherapies are used in treating multiple myeloma and related conditions in Norway. The study aims to fill knowledge gaps, provide evidence for future trials, and help develop guidelines for monitoring and managing side effects to improve patient survival and quality of life. This research focuses on patients with multiple myeloma, primary plasma cell leukemia, and AL amyloidosis. Participants are observed while receiving immunotherapies including Teclistamab, Elranatamab, Talquetamab, Idecabtagene vicleucel, and Ciltacabtagene Autoleucel as part of their routine care outside of clinical trials. The study monitors how these treatments are used in real-world settings, including dosing and administration. There is no assigned treatment group or placebo instead, the study collects data on treatments given during regular healthcare. Throughout the study, participants response to treatment, progression-free survival, time to next treatment, overall survival, and adverse events are tracked for up to ten years. Researchers collect data on infections, antibiotic resistance, airway viruses, and use of antimicrobial prophylaxis during therapy. This long-term monitoring aims to provide comprehensive safety and effectiveness information to guide future care and research.